Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Grifols Sa ADR (GIKLY)

Grifols Sa ADR (GIKLY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow 14.40
  • Price/Book 5.06
Trade GIKLY with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.9400 +12.31%
on 09/13/21
13.4100 unch
on 09/21/21
+1.6600 (+14.13%)
since 08/18/21
3-Month
11.7500 +14.13%
on 08/18/21
13.8600 -3.25%
on 06/23/21
-0.3300 (-2.40%)
since 06/15/21
52-Week
11.7500 +14.13%
on 08/18/21
15.6010 -14.04%
on 10/15/20
-0.5900 (-4.21%)
since 08/25/20

Most Recent Stories

More News
Grifols: Q2 Earnings Snapshot

BARCELONA, Spain (AP) _ Grifols SA (GRFS) on Thursday reported earnings of $164.9 million in its second quarter.

GRFS : 15.29 (-0.46%)
GIKLY : 13.4100 (+12.31%)
Grifols introduces HyperHEP B® (hepatitis B immune globulin [human]), a new formulation to treat patients exposed to hepatitis B

, /PRNewswire/ -- a leading global producer of plasma-derived medicines and provider of a variety of postexposure prophylaxis and IgG products for patients, today began commercializing HyperHEP B, a new...

GIKLY : 13.4100 (+12.31%)
GRF : 9.30 (-0.53%)
GRFS : 15.29 (-0.46%)
Grifols takes another step in the fight against Alzheimer's, partners with Ace to open first AMBAR® Center in Barcelona

- - , /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, and NASDAQ: GRFS), a leading global producer of plasma-derived medicines with a history of more than 110 years contributing to improve the health...

GIKLY : 13.4100 (+12.31%)
GRF : 9.30 (-0.53%)
GRFS : 15.29 (-0.46%)
Grifols: Q1 Earnings Snapshot

BARCELONA, Spain (AP) _ Grifols SA (GRFS) on Tuesday reported earnings of $156.7 million in its first quarter.

GRFS : 15.29 (-0.46%)
GIKLY : 13.4100 (+12.31%)
Grifols and Andorran government will establish world-class immunology research hub to expand global knowledge of the immune system and develop therapeutics

, /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, and NASDAQ: GRFS), a leading global producer of plasma-derived medicines with a history of more than 110 years contributing to improve the health and...

GIKLY : 13.4100 (+12.31%)
GRF : 9.30 (-0.53%)
GRFS : 15.29 (-0.46%)
Grifols Extends Commitment to World Federation of Hemophilia Humanitarian Aid Program to 2030

, /PRNewswire/ --Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of plasma-derived medicines with a track record of more than 100 years dedicated to enhancing people's...

GIKLY : 13.4100 (+12.31%)
GRF : 9.30 (-0.53%)
GRFS : 15.29 (-0.46%)
Grifols announces topline data from NIAID Phase 3 ITAC trial (INSIGHT-013) evaluating hyperimmune globulins as a treatment for hospitalized patients with COVID-19

, /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of plasma-derived medicines with a track record of more than 100 years dedicated to enhancing people's...

GIKLY : 13.4100 (+12.31%)
GRF : 9.30 (-0.53%)
GRFS : 15.29 (-0.46%)
Grifols installs first-ever DG Reader Net analyzer in North America

, /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the development of plasma-derived therapies and leader in the development of innovative diagnostic solutions, today...

GIKLY : 13.4100 (+12.31%)
GRF : 9.30 (-0.53%)
GRFS : 15.29 (-0.46%)
Grifols reinforces its innovation strategy after completing the acquisition of GigaGen to boost a novel method to generate a wide range of immunoglobulins

, /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P; NASDAQ: GRFS), a global healthcare company with a proven track record of more than 100 years dedicated to improving the health and well-being of people...

GIKLY : 13.4100 (+12.31%)
GRF : 9.30 (-0.53%)
GRFS : 15.29 (-0.46%)
Grifols fosters world's first scientific journal specialized in blood plasma

, /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P y NASDAQ: GRFS), a global leader in plasma-derived therapies with a more than 100-year track record of contributing to the health and well-being of people,...

GIKLY : 13.4100 (+12.31%)
GRF : 9.30 (-0.53%)
GRFS : 15.29 (-0.46%)

Key Turning Points

3rd Resistance Point 13.4100
2nd Resistance Point 13.4100
1st Resistance Point 13.4100
Last Price 13.4100
1st Support Level 13.4100
2nd Support Level 13.4100
3rd Support Level 13.4100

See More

52-Week High 15.6010
Fibonacci 61.8% 14.1299
Fibonacci 50% 13.6755
Last Price 13.4100
Fibonacci 38.2% 13.2211
52-Week Low 11.7500

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar